Eltrombopag
Generic Name: eltrombopag
Brand Names:
Eltrombopag Olamine
Eltrombopag is a thrombopoietin receptor agonist available as film-coated tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
Overview
Eltrombopag is a thrombopoietin receptor agonist available as film-coated tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
Uses
Indicated for treating thrombocytopenia in three contexts: persistent/chronic immune thrombocytopenia (ITP) in patients 1+ years, chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia in patients 2+ years.
Dosage
Initial dosing varies by indication: 50 mg daily for ITP (adults/pediatric 6+), 25 mg daily for hepatitis C, and 150 mg daily for first-line aplastic anemia (patients 12+).
Side Effects
Most common include anemia, nausea, pyrexia, alanine aminotransferase increased, cough, fatigue, headache, and diarrhea.
Interactions
Chelation with polyvalent cations. Transporter interactions with specific medications.
Warnings
BOXED WARNING: Risk of hepatic decompensation in chronic hepatitis C patients and hepatotoxicity risk with regular function monitoring. Hepatotoxicity, increased MDS progression risk, thrombotic complications, and cataracts require monitoring.
Pregnancy
Animal studies showed embryolethality at doses 6x human exposure. Insufficient human data available.
Frequently Asked Questions
What is Eltrombopag used for?▼
Indicated for treating thrombocytopenia in three contexts: persistent/chronic immune thrombocytopenia (ITP) in patients 1+ years, chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia in patients 2+ years.
What are the side effects of Eltrombopag?▼
Most common include anemia, nausea, pyrexia, alanine aminotransferase increased, cough, fatigue, headache, and diarrhea.
Can I take Eltrombopag during pregnancy?▼
Animal studies showed embryolethality at doses 6x human exposure. Insufficient human data available.
What are the important warnings for Eltrombopag?▼
BOXED WARNING: Risk of hepatic decompensation in chronic hepatitis C patients and hepatotoxicity risk with regular function monitoring. Hepatotoxicity, increased MDS progression risk, thrombotic complications, and cataracts require monitoring.
Related Medications
Epstein-barr Virus Nosode
epstein-barr virus nosode
PURPOSE: Epstein-Barr Virus Nosode - Exhaustion, Mucus Congestion, Fatigue
Perflutren
perflutren
Contrast Agent for Ultrasound Imaging [EPC]
11 DESCRIPTION DEFINITY RT (perflutren lipid microsphere) injectable suspension is, after activation, an ultrasound contrast agent for intravenous use. The perflutren lipid microspheres are composed of perflutren encapsulated in an outer lipid shell consisting of (R) – hexadecanoic acid, 1-[(phosphonoxy)methyl]-1,2-ethanediyl ester, monosodium salt (abbreviated DPPA); (R) - 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,4,9-trioxa-4-phosphapentacosan-1-aminium, 4-oxide, inner salt (a
Poison Treatment Adsorbent
poison treatment adsorbent
Purpose Poison adsorbent
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.